A total of 209 patients with malignancies, including MM and NSCLC treated with anti-PD-1 antibodies (62 with pembrolizumab, 147 with nivolumab), were enrolled in this study (Fig. 1, Table 1 and Table 2). This evidence concerns the gene PDCD1 and Miyoshi myopathy.